This panel will discuss the impact of recent Supreme Court and Federal Circuit decisions on Hatch-Waxman litigation. The panel will discuss the implications of these decisions on both innovator and generic companies.

Panel Moderator: Chandrika Vira, Director

Panelist: Lauren Rabinovic, Ph.D., Vice President and General Counsel, North Americas Generic IP, Teva Pharmaceuticals

Panelist: John Kirkland, Director of IP, Alkermes

Panelist: Dennies Varughese, Pharm.D., Director